News Releases

Cambridge, MA and Shanghai — July 17, 2019 — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, and Abbisko Therapeutics, a company with an extensive pipeline of ...

Global 4WHIM trial marks first-ever Phase 3 study in patients with WHIM syndrome CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 26, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq:XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatme...

Genetic testing to enable improved patient diagnoses and provide valuable disease-specific genetic insights for X4 clinical development of novel therapies CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 12, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutic...

Mavorixafor selected for LLS’s Therapy Acceleration Program ® (TAP) CAMBRIDGE, Mass. & RYE BROOK, N.Y. --(BUSINESS WIRE)--May 15, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq:XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 24, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of E....

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 12, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today the pricing of its previously announced und...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 11, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today that it has commenced an underwritten publi...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of Murray Stewart , M.D., as...

Expects to commence the global Phase 3 pivotal trial of mavorixafor for the treatment of patients with Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome in second quarter 2019 having finalized the protocol based on FDA guidance Receives World Health Organ...

– Newly Nasdaq-listed XFOR focused on the development of novel therapeutics for the treatment of rare diseases – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 13, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR, as of March 14, 2019 ), a clinical-stage biopharmaceutical company focused ...